Du är här

2015-09-04

Swedish Orphan Biovitrum AB (publ): Sobi celebrates 25 years with Orfadin® (nitisinone) - a result of ground-breaking Swedish research

To acknowledge that it is 25 years since the first person with the rare
genetic disease Hereditary Tyrosinaemia type 1 (HT-1) was treated in clinical
trials with Orfadin® (nitisinone),Swedish Orphan BiovitrumAB (publ) (Sobi)
(STO: SOBI) hosted a satellite symposium in Lyon, France in conjunction with
the annual SSIEM symposium, Society for the Study of Inborn Errors of
Metabolism. HT-1 is a progressive disease that affects infants and children,
may result in liver and kidney failure and can be fatal if it is not
diagnosed and treated early in life.

The symposium honoured Professor Elisabeth Holme and Professor Sven Lindstedt,
two Swedish pioneers in the research of HT-1, both of whom passed away
earlier this year. Professor Lindstedt led a group at University of
Gothenburg who developed and presented ground-breaking research into HT-1. He
and his group established the primary aetiology behind the disease, which led
to the discovery of nitisinone. Today Orfadin® (nitisinone) is first line
therapy, having replaced liver transplantation, as standard care.

"Thanks to these visionary individuals and to the conduct of research that led
to the development of nitisinone, people with HT-1 who 25 years ago had short
life expectancy as a consequence of the natural course of the disease, have
the possibility of therapeutic intervention that may even allow them to
become grandparents", says Birgitte Volck, Chief Medical Officer of Sobi.

Before pharmacological treatment was available, less than one third of infants
diagnosed with HT-1 before two months of age lived past their second
birthday.[1] Treatment with Orfadin, combined with dietary restriction of
tyrosine and phenylalanine; and more widespread new-born screening leading to
early diagnosis have dramatically improved the outcomes for HT-1 patients.[2]

Orfadin is approved in the EU, USA and several other countries for the
treatment of patients with confirmed diagnosis of hereditary tyrosinaemia
type 1 (HT-1) in combination with dietary restriction of tyrosine and
phenylalanine. HT-1 is a progressive disease where the body lacks the ability
to break down the amino acid tyrosine. Without treatment, HT-1 is ultimately
fatal. Orfadin, together with the appropriate diet, is an essential part of
effective HT-1 treatment.

---

About Orfadin

Orfadin (nitisinone) blocks the breakdown of tyrosine, thereby reducing the
amount of toxic by-products in the body. People with Hereditary Tyrosinaemia
type-1 (HT-1) have problems breaking down an amino acid called tyrosine.
Toxic by-products are formed and accumulate in the body, which can cause
liver failure, renal dysfunction and neurological complications. In the most
common form of the disease, symptoms arise within the first six months of the
child's life. Patients must maintain a special diet in combination with
Orfadin treatment as tyrosine remains in the body. Approximately 1,000
persons are identified as living with HT-1 today. Orfadin is a proprietary
product and is developed by and marketed globally by Sobi.

About Sobi

Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on Haemophilia, Inflammation and Genetic diseases. We also market a
portfolio of specialty and rare disease products for partner companies across
Europe, the Middle East, North Africa and Russia. Sobi is a pioneer in
biotechnology with world-class capabilities in protein biochemistry and
biologics manufacturing. In 2014, Sobi had total revenues of SEK 2.6 billion
(USD 380 M) and about 600 employees. The share (STO: SOBI) is listed on
NASDAQ OMX Stockholm. More information is available at www.sobi.com.

For more information please contact

----------------------------------------------------------------------------------------------------
| Media relations Investor relations |
| Oskar Bosson, Head of Communications Jörgen Winroth, Vice President, Head of Investor Relations |
| T: +46 70 410 71 80 T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135 |
| oskar.bosson@sobi.com jorgen.winroth@sobi.com |
----------------------------------------------------------------------------------------------------

[1] van Spronsen FJ, Thomasse Y, Smit GP, et al. Hepatology. 1994;
20(5):1187-1191

[2] Orfadin EPAR: Product information 25/07/2015 Orfadin -EMEA/H/C/000555
-IB/004

031e_25 years with Orfadin
http://hugin.info/134557/R/1949732/708697.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Globenewswire

HUG#1949732

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.